Showing 1581-1590 of 3020 results for "".
- Former Deputy Attorney General Appointed To Advise Valeant's Ad Hoc Committeehttps://practicaldermatology.com/news/former-deputy-attorney-general-appointed-to-advise-valeants-ad-hoc-committee/2458830/Valeant Pharmaceuticals International, Inc.’s ad hoc committee appointed by Valeant's board of directors has appointed former Deputy Attorney General of the United States Mark Filip of Kirkland & Ellis LLP to advise the committee in its review of allegations related to Valeant's
- Agents for Advanced Melanoma Among Prix Galien USA 2015 Award Recipientshttps://practicaldermatology.com/news/agents-for-melanoma-among-prix-galien-usa-2015-award-recipients/2458832/The Prix Galien USA 2015 Awards have been bestowed on Imbruvica® (ibrutinib) for best pharmaceutical agent, Opdivo® (nivolumab) and Keytruda® (pembrolizumab) for best biotechnology product, and the T2Candida Panel for best medical technology. 
- New Therapeutic Skin Care Line From Galdermahttps://practicaldermatology.com/news/new-therapeutic-skin-care-line-from-galderma/2458852/Galderma Laboratories, LP, makers of Cetaphil, unveiled a new therapeutic skincare line precisely engineered for challenged skin—Excipial. It will be available over the counter and without a prescription. Excipial products are formulated with ingredients to heal, relieve, protect, and repai
- Scleroderma Foundation to Honor Genentech's Dr. Jeffrey Siegel for Scientific Contributionshttps://practicaldermatology.com/news/scleroderma-foundation-to-honor-genentechs-dr-jeffrey-siegel-for-scientific-contributions/2458864/Dr. Jeffrey Siegel, Senior Group Medical Director of Immunology at Genentech, will be honored by the Scleroderma Foundation of Southern California with the Spirit of Leadership Award at their 17th annual “Key to a Cure” gala, which will be held on Saturday, Octobe
- 100,000 Join the ASPIRE Galderma Rewards Loyalty Program in First 90 dayshttps://practicaldermatology.com/news/100000-join-the-aspire-galderma-rewards-loyalty-program-in-the-first-90-days/2458867/Galderma’s ASPIRE Rewards program has enrolled 100,000 consumers since its launch on May 1, 2015. ASPIRE Galderma Rewards is a new loyalty program connecting US consumers and healthcare professionals using the Galderma family of aesthetic products. The vision of the Galderma a
- Report Predicts Growth in Global Dermatology Diagnostic Devices Market 2015-2019https://practicaldermatology.com/news/report-predicts-growth-in-global-dermatology-diagnostic-devices-market-2015-2019/2458869/A recently published report, Global Dermatology Diagnostic Devices Market 2015-2019, which was prepared based on an in-depth market analysis with inputs from industry experts
- FDA Warns of Severe Adverse Events with Application of Picato (ingenol mebutate) Gel; Requires Label Changeshttps://practicaldermatology.com/news/fda-warns-of-severe-adverse-events-with-application-of-picato-ingenol-mebutate-gel-requires-label-changes/2458878/The FDA released a Drug Safety Communication to warn about reports of severe allergic reactions and herpes zoster (shingles) associated with the use of Picato gel (ingenol mebutate), which is approved to treat actinic keratosis. The FDA said it also received reports of cases involving sev
- Genentech Initiates Phase III Trial of Rituximab in Pemphigus Vulgarishttps://practicaldermatology.com/news/genentech-initiates-phase-iii-trial-of-rituximab-in-pemphigus-vulgaris/2458885/Genentech has initiated a Phase III clinical trial investigating the use of Rituxan (rituximab) in patients with pemphigus vulgaris (PV). The aim of the PEMPHIX study is to determin
- GW School of Medicine and Health Sciences Announces New Dermatology Residency Programhttps://practicaldermatology.com/news/gw-school-of-medicine-and-health-sciences-announces-new-dermatology-residency-program/2458895/The George Washington University (GW) School of Medicine and Health Sciences (SMHS) is pleased to announce a new dermatology residency program that began on July 1, 2015. This unique training experience is open to national and international medical students, who will learn to provide the
- Nuvo Research Granted US Patent for Topical Onychomycosis Formulationhttps://practicaldermatology.com/news/nuvo-research-granted-us-patent-for-topical-onychomycosis-formulation/2458896/The United States Patent and Trademark Office granted a new U.S. patent number 9,084,754 ('754 Patent) to Nuvo Research Inc. for its highly permeating topical formulations of terbinafine, an antifungal drug, and methods for treating onychomycosis. The '754 Patent will expire on March 8, 2